What if cancer cells could be re-engineered to turn against their own kind?
A new study in Science Translational Medicine, led by researchers at Brigham and Women’s Hospital, leverages the power of gene editing to take a critical step toward using cancer cells to kill cancer. The team reports promising results in preclinical models across multiple types of cancer cells, establishing a potential roadmap toward clinical translation for treating primary, recurrent and metastatic cancer.
“This is just the tip of the iceberg,” said corresponding author Khalid Shah MS, PhD, director of the Center for Stem Cell Therapeutics and Imaging (CSTI) in the BWH Department of Neurosurgery and faculty at Harvard Medical School and Harvard Stem Cell Institute (HSCI). “Cell-based therapies hold tremendous promise for delivering therapeutic agents to tumors and may provide treatment options where standard therapy has failed. With our technique, we show it is possible to reverse-engineer a patient’s own cancer cells and use them to treat cancer. We think this has many implications and could be applicable across all cancer cell types.”
The new approach capitalizes on cancer cells’ self-homing ability – the process in which cancer cells can track the cells of their kind that have spread within the same organ or to other parts of the body. Harnessing this power could overcome drug delivery challenges, helping get therapeutics to tumor sites that may otherwise be difficult to reach.
The team developed and tested two techniques to harness the power of cancer cells. The “off the shelf” technique used pre-engineered tumor cells that would need to be matched to a patient’s HLA phenotype (essentially, a person’s immune fingerprint). The “autologous” approach used CRISPR technology to edit the genome of a patient’s cancer cells and insert therapeutic molecules. These cells could then be transferred back into the patient.
To test both approaches, the team used mouse models of primary and recurrent brain cancer and breast cancer that has spread to the brain. The team saw direct migration of engineered cells to the sites of tumors and found evidence that the engineered cells specifically targeted and killed recurrent and metastatic cancer in the mice. The researchers report that the treatment increased the survival of the mice. Engineered cells were equipped with a “kill switch” that could be activated after treatment – PET imaging showed that this kill switch worked to eliminate the cells.
“Our study demonstrates the therapeutic potential of using engineered tumor cells and their self-homing properties for developing receptor-targeted therapeutics for various cancers,” said Shah.
Learn more: Engineered Cancer Cells Can Fight Primary and Metastatic Cancer
The Latest on: Engineered cancer cells
[google_news title=”” keyword=”engineered cancer cells” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Engineered cancer cells
- Multiply Labs and GenScript partner on cell isolation automationon April 26, 2024 at 6:39 am
Robotics company Multiply Labs has partnered with global life-sciences service provider GenScript Biotech to automate the cell isolation phase in cell therapy manufacturing.
- MIT study reveals circadian impact on drug metabolism in engineered liverson April 25, 2024 at 10:51 pm
Giving drugs at different times of day could significantly affect how they are metabolized in the liver, according to a new study from MIT.
- CAR T-Cells and Safety Signals — ITT Episode 29on April 24, 2024 at 2:11 pm
This podcast episode examines CAR T-cell therapy’s early successes, broader promise, and emerging risks, as the FDA considers reports of occasional secondary cancers.
- Pfizer gets grant for treatment of cancer using engineered immune cells targeting bcmaon April 24, 2024 at 6:18 am
Discover how Pfizer's patented CARs targeting BCMA offer a groundbreaking method for treating cancer. Learn about the unique ligand-binding and signaling domains for effective treatment.
- CAR T cell therapy targeting HER2 antigen shows promise against advanced sarcoma in phase I trialon April 23, 2024 at 5:00 am
Researchers at Texas Children’s Cancer Center and the Center for Cell and Gene Therapy at Baylor College of Medicine, Texas Children’s Hospital ...
- UCSF Scientists Build a Molecular “GPS” to Guide Cell Therapieson April 22, 2024 at 10:52 am
Wendell Lim earns $30 million contract from ARPA-H to develop a cellular toolkit for therapies targeting diseases of the brain and lung.
- Engineered peptides show promise in cancer immunotherapyon April 22, 2024 at 6:49 am
In a new study published today in Nature Biomedical Engineering, researchers at The University of Texas MD Anderson Cancer Center have designed a new method for developing immunotherapy drugs using ...
- Engineered Peptides Open New Avenue for Immunotherapyon April 22, 2024 at 2:24 am
The immune system is built to identify and eliminate diseased cells, but cancer cells often avoid detection. Researchers have designed a new method for developing immunotherapy drugs using engineered ...
- Cancer cure one step closeron April 21, 2024 at 9:13 pm
The science of fighting cancer has been taken to new levels, thanks to two independent research teams, one of which is in Australia. Each team has published an ...
via Bing News